Clinical Trials Browser

Neoplasm Metastasis × atezolizumab × Gynecologic × Clear all

Carcinosarcoma, Disease, Neoplasm Metastasis, Obesity, Endometrial Neoplasms

NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06099418 2024-09-20

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Phase 2 Withdrawn

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT04405349 2023-12-15

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Phase 2 Completed

52 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

Clinical Trials

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer